Leadership Team

Frank Bedu Addo PDS

Frank Bedu-Addo, Ph.D.
Chief Executive Officer, Director

Dr. Bedu-Addo has served as a director, president and CEO of PDS Biotech since its inception in 2005. Dr. Bedu-Addo is a veteran biotech executive with experience successfully starting and growing biotechnology organizations. He has been responsible for the development and implementation of both operational and drug development strategies, supervising and managing both large organizations and emerging biotechnology companies. Dr. Bedu-Addo was a founding and senior executive at KBI BioPharma, Inc. As Vice President of Drug Development, he oversaw all business and drug development operations. Before his tenure at KBI, he successfully started and managed Cardinal Health’s East Coast biotechnology drug development operations. Prior to Cardinal Health, Dr. Bedu-Addo was an Associate Director at Akzo-Nobel, Senior Scientist at Elan (The Liposome Co.), and Principal Scientist at Schering-Plough. In these positions, he contributed to the development of numerous drugs, including antiviral and anticancer products. Dr. Bedu-Addo obtained his M.S. in Chemical Engineering and Ph.D. in Pharmaceutics from the University of Pittsburgh.

Gregory Conn

Gregory Conn, Ph.D.
Chief Scientific Officer

Dr. Conn has more than 35 years of drug-development expertise, including development of antiviral and anticancer drugs through to commercialization. He is a graduate of the Albert Einstein College of Medicine, where he obtained both his M.S. and Ph.D., discovering novel angiogenic molecules in the human brain. Dr. Conn started his pharmaceutical career at Merck, Sharpe, and Dohme, where he continued his work on novel angiogenic factors, discovering and characterizing the VEGF family of growth factors, work which led to the development and commercialization of the anti-cancer drug Avastin. He was later a leading scientist at Regeneron Pharmaceuticals, where he established and headed various groups in the Cell and Molecular Biology and Drug Discovery departments. Dr. Conn subsequently became a Director in the Process Development department at Covance Biotechnology Services Inc., a contract research and development and drug manufacturing organization, where he supervised the analytical development teams responsible for drug characterization, method development and drug stability studies, and program teams responsible for developing drug manufacturing processes. Dr. Conn has expertise across all phases of the drug development process, including FDA and regulatory requirements, is the co-inventor of eight drug patents, and was a founding member of the PDS team as CSO.

Lauren V. Wood

Lauren V. Wood, M.D.
Chief Medical Officer

Dr. Wood joined PDS Biotech as Chief Medical Officer in February 2019.  She has overall responsibility for clinical development of the novel, immune activating Versamune® platform product pipeline targeting HPV-related pre-cancer and advanced cancers as well as a broad spectrum of solid tumors.  With 30 years of extensive clinical research experience at the National Institutes of Health, Dr. Wood most recently was the Clinical Director of the Vaccine Branch, Center for Cancer Research, National Cancer Institute.  While there she oversaw the translational development of immune-based therapies for both cancer and HIV infection and was a co-inventor of two patented therapeutic cancer vaccine platforms targeting the TARP and HER tumor antigens.Prior to joining the Vaccine Branch, Dr. Wood was a Senior Clinical Investigator from 1992-2009 in the NCI Pediatric Oncology and HIV and AIDS Malignancy Branches, overseeing teams investigating antiretroviral, anti-infective, and immunomodulatory therapies for HIV-infected children, adolescents and young adults.  Trained in both Internal Medicine and Pediatrics with subspecialty training in Allergy and Immunology from NIAID, Dr. Wood received her M.D. from Duke University School of Medicine and B.A. in Biology from Oberlin College.

Mark Baxter

Mark Baxter, Ph.D.
Senior Vice President of Global Quality

Dr. Baxter has more than 31 years of pharmaceutical Quality expertise, including quality oversight responsibilities ranging from early development through product commercialization. He is a graduate of Villanova University where he obtained a Ph.D., in Inorganic Chemistry studying binding constants between heavy metals and various carbohydrates. Dr. Baxter started his pharmaceutical career at Merck & Co., Inc., where he held various QC and QA leadership roles overseeing laboratory operations, sterile and non-sterile manufacturing and API production. Dr. Baxter held senior quality leadership roles at Schering-Plough where he oversaw all pharmaceutical quality operation activities throughout Europe and the Americas. More recently, Dr. Baxter held senior quality leadership roles in emerging biotech companies including Edge Therapeutics and Advaxis Immunotherapies.

Joe Dervan

Joe Dervan, Ph.D.
Vice President of Research and Development

Dr. Dervan has more than 20 years of biopharmaceutical drug-development expertise, from bench to commercialization, including development of a broad range of immuno-oncology therapeutics. He is a graduate of Sheffield University Medical School, UK, where he obtained his Ph.D., in Molecular Medicine, researching protein-DNA interactions, and publishing his work in the Proceedings of the National Academy of Sciences USA and Nature Structural and Molecular Biology. He went on to undertake postdoctoral work within the department of Molecular Biophysics & Biochemistry at Yale University and completed an MBA at Warwick University Business School, UK.
Dr. Dervan started his pharmaceutical career at Pfizer, UK where he performed bioanalysis of a range of corticosteroids and related prodrugs. He also worked within the field of proteomics utilizing the world’s first genome sequences at F. Hoffmann-La Roche, Basel, Switzerland. Following his postdoc, he worked at Protalex, Inc, as Director of Protein Chemistry and Biopharmaceutical Manufacturing where he oversaw laboratory operations, drug substance and drug product development, and manufacturing operations. Following his time at Protalex, Inc, Dr. Dervan worked as a senior consultant for several biotech companies. Prior to joining PDS Biotech, he held leadership roles at GSK where he lead multiple analytical lifecycle management project teams, supporting global development of a broad range of mid-late phase biopharmaceutical assets.

Deanne Randolph

Deanne Randolph
Vice President of Commercial Development

Ms. Randolph is an accomplished pharmaceutical/biotech commercial leader with more than 20-years of high-impact contributions to large multinational corporations as well as clinical stage biotech companies. From early development through commercialization, Ms. Randolph has led multiple US, European, and global pharmaceutical and biotechnology product launches. She has experience in both primary and secondary care across a broad range of therapeutic areas including immunology, oncology, and rare disease. Prior to joining PDS Biotech, she led Sante Group, a consultancy she founded to provide expertise in strategic pre-launch planning, positioning, life cycle management and clinical development strategy to pharmaceutical and biotech clients preparing for commercialization. Prior to consulting, Ms. Randolph held commercial leadership roles in both the US and Europe at Pfizer, Johnson & Johnson, and at Bayer. She holds both an MBA and a BA from Wake Forest University.

Deanne Randolph

Gregory Reid
Vice President of Program Development

Mr. Reid has amassed 30+ years’ experience in the pharmaceutical industry, chiefly in drug development. He brings this breadth of experience to PDS Biotech to support the advancement of the company’s innovative pipeline.While Mr. Reid has obtained substantial operational experience in large pharma and large clinical research organizations (CROs), the majority of his experience has been acquired working with biotech firms where he has skillfully guided teams to successfully bring several novel molecules targeting oncology and antifungal therapies from the bench through development. Mr. Reid has led development programs in North America, Europe and Asia. He holds a M.Sc. in immunology from McGill University and an MBA from the John Molson School of Business at Concordia University and has authored more than 20 peer-reviewed manuscripts and abstracts.

Nathalie Riebel

Nathalie Riebel
Vice President of Clinical Operations

Ms. Riebel joined PDS Biotech in June 2019 as the Vice President of Clinical Operations. She is responsible for the operational execution of the PDS Biotech pipeline. She brings 30 years of clinical research experience across the industry. Before joining PDS Biotech, Mrs. Riebel held a leadership role at Delcath Systems for oncology devices and Eli Lilly and Co. as Director of Global Quality/Inspection readiness. As Director of Clinical Operations at GSK, Imclone Systems, and ICON Clinical Research, she skillfully guided cross-functional global teams to achieve clinical deliverables and submissions.

Hillary Yegen

Hillary Yegen
Vice President of Legal

Ms. Yegen joined PDS Biotech in May 2019, to head the company’s legal department. Ms. Yegen has over 15+ years of health care law expertise across public and private biotech, hospital systems, private practice and nonprofit Boards where she has provided critical strategic advisory to C-Suite Executive management and the Board of Directors. Prior to PDS Biotech, Ms. Yegen held the position of Senior Commercial Counsel for Axiom Law, where she garnered extensive healthcare legal and compliance client advisory expertise, providing in-house counsel to industry-leading health care and pharmaceutical companies including Edge Therapeutics, CarePoint Health System, Hartford Health and Connective Rx. Ms. Yegen began her legal career in 2005, building more than 10 years of litigation experience in the private practice space where she counseled a variety of health care clients.Ms. Yegen attained her Juris Doctorate (JD) from American University and her Bachelor of Science (BS) Degree in Biopsychology from the University of Michigan. She is certified in healthcare compliance (CHC) from Seton Hall Law.

Receive Email Alerts

Join our mailing list to receive the latest news and updates from our team.

Sign up